CheckMate914

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis - ScienceDirect

Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade

Adjuvant Immunotherapy in Resected Renal Cell Carcinoma: Déjà vu or Progress?

日本がん対策図鑑 【腎細胞がん：術後治療（DFS）】「オプジーボ＋ヤーボイ」vs「経過観察」

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Followin

Toni Choueiri, MD on X: Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the @TheLancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could

EIKCS 2022: Selecting Renal Cell Carcinoma Patients for Adjuvant Therapy